What does selumetinib do?
What does selumetinib do?
Selumetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals the tumors to grow. This helps to stop or slow tumor growth.
Is Selumetinib FDA approved?
On April 10, 2020, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca) for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Who developed Selumetinib?
Selumetinib is a MEK 1/2 Inhibitor being co-developed by AstraZeneca and MSD. AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc.
What is a plexiform?
(PLEK-sih-form NOOR-oh-fy-BROH-muh) A tumor that forms in the tissue that covers and protects the nerves. Plexiform neurofibromas can occur anywhere in the body outside of the brain and spinal cord. They can occur on the face (including around the eye), neck, arms, legs, back, chest, abdomen, and internal organs.
Can adults take Selumetinib?
Selumetinib will be administered at a dose of 50 mg BID on a continuous dosing schedule (1 cycle=28 days), which is the recommended adult dose.
Is Selumetinib a chemotherapy drug?
What is Selumetinib? Selumetinib (MEK inhibitor AZD6244) is a type of medicine called a targeted therapy. Selumetinib acts to block certain cell signals that may help keep cancer cells from growing. Selumetinib is an investigational drug being studied for several types of cancers.
Is Selumetinib available in the UK?
In the UK, Selumetinib is currently available for children and adults on compassionate basis only via the national centres in London and Manchester.
Who is Inn Selumetinib?
Selumetinib ( INN ), sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth.
What is MPNST?
Malignant Peripheral Nerve Sheath Tumor, or MPNST, is a cancer of the cells that form the sheath that covers and protects peripheral nerves. Peripheral nerves are those outside of the central nervous system (brain and spinal cord).
What is Mirdametinib?
Mirdametinib is an investigational oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined …